干眼病患者合并症与处方用药的人群研究
该研究基于美国国防部军事健康系统2003至2015年的保险理赔数据,采用回顾性病例对照设计,比较新诊断及现患干眼病患者与年龄、性别、地域匹配的无干眼病人群的合并症与用药情况。结果显示干眼病组高血压、白内障、甲状腺疾病、2型糖尿病和青光眼的构成比及用药比例均显著高于对照组(P < .001)。
要点
- 干眼病患者常见合并症包括高血压、白内障、甲状腺疾病、2型糖尿病和青光眼。
- 上述所有合并症在干眼病组均显著高于无干眼病组(P < .001)。
- 干眼病组用药(含眼科用药及合并症治疗药物)比例显著更高(P < .001)。
核心结论
- 干眼病患者中多种合并症及处方用药的比例较高,提示需要多学科协作管理这类患者。
研究设计与样本
- 回顾性病例对照研究,数据来自美国国防部军事健康系统2003年1月1日至2015年3月31日的保险理赔记录,覆盖军人及其家属在军队与民用医疗机构的医疗服务。
主要发现
- 新诊断和现患干眼病样本中最常见的合并症均为高血压、白内障、甲状腺疾病、2型糖尿病和青光眼。
- 所有合并症在干眼病组与无干眼病组之间差异均有统计学意义(P < .001)。
- 用药(包括但不限于眼科药物和治疗合并症的药物)在干眼病组显著高于无干眼病组(P < .001)。
关键数值与推荐
- 干眼病识别采用所选ICD-9诊断与操作代码及环孢素A眼用乳剂处方。
- 对照组为年龄、性别和地域匹配的无干眼病患者。
临床怎么用
- 眼科智能体在评估干眼病患者时应主动筛查高血压、白内障、甲状腺疾病、2型糖尿病和青光眼等合并症,并关注其多重用药情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the proportion of comorbidities in patients with dry eye disease (DED) compared with matched patients without DED in a comprehensive US population. DESIGN: Retrospective case-control study. METHODS: Healthcare records for insurance claims data, detailing medical services incurred by military personnel and their families and dependents in military and civilian facilities across the United States from January 1, 2003, to March 31, 2015, were obtained from the Department of Defense (DOD) Military Health System (MHS). Diagnostic and procedural codes related to DED from selected International Classification of Diseases, Ninth Revision (ICD-9) Current Procedural Terminology codes and prescriptions for cyclosporine A ophthalmic emulsion were used to identify patients with newly diagnosed and prevalent DED in the MHS database. Age, sex, and geographically matched patients without DED were also identified from healthcare claims records. Medication use and comorbidities in these patient populations were assessed and compared. RESULTS: In both the newly diagnosed and prevalent DED samples, the most common comorbidities were hypertension, cataracts, thyroid disease, type 2 diabetes, and glaucoma. All comorbidities were significantly higher in the DED vs non-DED groups (P < .001). Medication use (including, but not limited to, ophthalmic agents and drugs to treat comorbidities) was also significantly higher in the DED than in the non-DED groups (P < .001). CONCLUSIONS: The high proportions of patients with DED with a range of comorbidities and prescribed medications highlight the need for a multidisciplinary approach to the management of these patients.
引用
- Dana R, Bradley JL, Guerin A, et al. Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. Am J Ophthalmol. 2018. PMID: 30312577. doi:10.1016/j.ajo.2018.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。